Relive the excitement of the Patriots’ path to their fourth Super Bowl Championship with “Pumped,” a special commemorative book from The Boston Globe.

FDA sees heart risk in J&J drug

Johnson & Johnson’s experimental diabetes drug might bring minor heart risks because it raised cholesterol levels in patient testing, according to federal drug reviewers.

In documents released Tuesday, Food and Drug Administration staff experts conclude studies showed J&J’s canagliflozin raised levels of LDL, or bad cholesterol, and slightly increased risk of heart attack, stroke, or death, compared to two other types of diabetes medications.

Continue reading below

Studies also showed the pill increased risks of urinary tract infections and fungal infections in the genital area. That’s because canagliflozin works by boosting blood sugar excretion via urine, and germs thrive on that sugar.

The studies didn’t find other serious problems.

Outside advisers to the FDA will review the data during a meeting Thursday and recommend whether the agency should approve canagliflozin.

Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking. Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com